CCL

Összesen 21 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM033051
035-os BibID:PMID:21505766 WOS:000293238300015
Első szerző:Baksay Beáta
Cím:Coexistence of ankylosing spondylitis and rheumatoid arthritis in a female patient / Beáta Baksay, Alíz Dér, Zoltán Szekanecz, Sándor Szántó, Attila Kovács
Dátum:2011
ISSN:0770-3198
Megjegyzések:Ankylosing spondylitis (AS) and rheumatoid arthritis (RA) are two distinguished representatives of inflammatory rheumatic diseases. The two diseases differ significantly in their etiology, pathology, clinical signs, and in the nature of articular manifestations. Their association has been a rarity in the literature. Here, authors describe a case of a 55-year-old female patient with AS associated with RA. Her spinal symptoms started in 1979, and the diagnosis of AS was established based on the typical clinical picture and X-ray. She developed severe spinal deformity during the next decades. In 2005, peripheral polyarthritis developed, although neither the diagnosis nor the treatment was modified. In 2007, authors diagnosed seropositive RA. Therapy included anti-inflammatory therapy and traditional disease-modifying agents, eventually followed by biological therapy.
Tárgyszavak:Orvostudományok Klinikai orvostudományok levél
egyetemen (Magyarországon) készült közlemény
Megjelenés:Clinical Rheumatology. - 30 : 8 (2011), p. 1119-1122. -
További szerzők:Dér Alíz Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Szántó Sándor (1968-) (belgyógyász, reumatológus) Kovács Attila (reumatológus)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
DOI
Borító:

2.

001-es BibID:BIBFORM007047
Első szerző:Biró Edit
Cím:Association of systemic and thyroid autoimmune diseases / Biro, E., Szekanecz, Z., Czirjak, L., Danko, K., Kiss, E., Szabo, N. A., Szucs, G., Zeher, M., Bodolay, E., Szegedi, G., Bako, G.
Dátum:2006
ISSN:0770-3198 (Print)
Megjegyzések:There are few large cohort studies available on the association of systemic and thyroid autoimmune diseases. In this study, we wished to determine the association of Hashimoto's thyroiditis (HT) and Graves' disease (GD) with systemic autoimmune diseases. METHODS: One thousand five hundred and seventeen patients with systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (SSc), mixed connective tissue disease (MCTD), Sjogren's syndrome (SS) and polymyositis/dermatomyositis (PM/DM) were included in the study. The HT and GD were diagnosed based on thorough clinical evaluation, imaging and fine-needle aspiration cytology (FNAC). The frequency of HT and GD in these diseases was assessed. In addition, 426 patients with HT or GD were assessed and the incidence of SLE, RA, SSc, MCTD, SS and PM/DM among these patients was determined. Prevalence ratios indicating the prevalences of GD or HT among our autoimmune patients in comparison to prevalences of GD or HT in the general population were calculated. RESULTS: Altogether 8.2% of systemic autoimmune patients had either HT or GD. MCTD and SS most frequently overlapped with autoimmune thyroid diseases (24 and 10%, respectively). HT was more common among MCTD, SS and RA patients (21, 7 and 6%, respectively) than GD (2.5, 3 and 1.6%, respectively). The prevalences of HT in SLE, RA, SSc, MCTD, SS and PM/DM were 90-, 160-, 220-, 556-, 176- and 69-fold higher than in the general population, respectively. The prevalences of GD in the same systemic diseases were 68-, 50-, 102-, 76-, 74- and 37-fold higher than in the general population, respectively. Among all thyroid patients, 30% had associated systemic disease. In particular, 51% of HT and only 16% of GD subjects had any of the systemic disorders. MCTD, SS, SLE, RA, SSc and PM/DM were all more common among HT patients (20, 17, 7, 4, 2 and 2%, respectively) than in GD individuals (2, 5, 5, 1, 2 and 1%, respectively). CONCLUSION: Systemic and thyroid autoimmune diseases often overlap with each other. HT and GD may be most common among MCTD, SSc and SS patients. On the other hand, these systemic diseases are often present in HT subjects. Therefore it is clinically important to screen patients with systemic autoimmune diseases for the co-existence of thyroid disorders.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Arthritis, Rheumatoid
Autoimmune Diseases
Dermatomyositis
Female
Graves Disease
Hashimoto Disease
Humans
Lupus Erythematosus, Systemic
Male
Middle Aged
Mixed Connective Tissue Disease
Prevalence
Scleroderma, Systemic
Sjogren's Syndrome
Megjelenés:Clinical Rheumatology. - 25 : 2 (2006), p. 240-245. -
További szerzők:Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Czirják László Dankó Katalin (1952-2021) (belgyógyász, allergológus és klinikai immunológus) Kiss Emese (1960-) (belgyógyász, immunológus) Szabó Nóra Anna (1976-) (orvos) Szűcs Gabriella (1963-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Zeher Margit (1957-2018) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Bodolay Edit (1950-) (belgyógyász, allergológus és klinikai immunológus) Szegedi Gyula (1936-2013) (belgyógyász, immunológus) Bakó Gyula (1951-) (belgyógyász)
Internet cím:elektronikus változat
DOI
elektronikus változat
Borító:

3.

001-es BibID:BIBFORM007050
Első szerző:Bodolay Edit (belgyógyász, allergológus és klinikai immunológus)
Cím:Five-year follow-up of 665 Hungarian patients with undifferentiated connective tissue disease (UCTD) / Bodolay, E., Csiki, Z., Szekanecz, Z., Ben, T., Kiss, E., Zeher, M., Szucs, G., Danko, K., Szegedi, G.
Dátum:2003
ISSN:0392-856X (Print)
Megjegyzések:To determine the clinical symptoms and the panel of autoantibodies of patients with early undifferentiated connective tissue disease (UCTD) followed for at least 1 year. METHODS: 716 UCTD patients with manifestations suggestive but not diagnostic of specific connective tissue disease (CTD) were recruited and followed up between 1994-1999. The patients with early UCTD were subdivided into those with isolated Raynaud's phenomenon (RP) (50 patients), unexplained polyarthritis (31 patients) and "true" UCTD (665 patients). UCTD was diagnosed on the basis of clinical manifestations suggestive of a connective tissue disease and the presence of at least one non-organ specific autoantibody. The patients' sera were tested for anti-nuclear (ANA), as well as for nine different specific autoantibodies (anti-dsDNA, -Sm, -RNP, -SSA, -SSB, -Scl-70, -centromere, -Jo1 and -PM-Scl). RESULTS: The most common clinical manifestations of UCTD included RP, arthritis/arthralgias, pleuritis/pericarditis, sicca symptoms, cutaneous involvement (photosensitivity, rash), central nervous symptoms, peripheral neuropathy, fever, vasculitis, less pulmonary involvement and myositis. 230 of the 665 true UCTD patients (34.5%) developed a defined CTD (28 systemic lupus erythematosus [SLE], 26 mixed connective tissue disease [MCTD], 19 progressive systemic sclerosis [PSS], 45 Sjogren's syndrome, 3 polymyositis/dermatomyositis [PM/DM], 87 rheumatoid arthritis [RA], and 22 systemic vasculitis. 435 of 665 patients (65.4%) remained in the UCTD state, and 82 of 665 patients (12.3%) achieved complete remission with symptoms not reappearing within the 5-year period. The highest probability of evolution to a defined CTD was during the first 2 years after onset: of 230 UCTD patients 183 (79.5%) developed major organ symptoms and signs. In particular skin and cardiac complications seemed to spread during the follow-up period in those patients who progressed to SLE. The condition of 18/50 patients with isolated RP evolved to UCTD and 3 of 31 patients with unexplained polyarthritis progressed to definite CTD (2 patients RA and one MCTD). CONCLUSION: In our study most of the UCTD patients did not develop a definite CTD, but during the follow-up period we found new clinical and serological manifestations. One-third of the UCTD patients showed progress into different types of specific CTD.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Adolescent
Adult
Aged
Autoantibodies
Autoimmunity
Cohort Studies
Confidence Intervals
Connective Tissue Diseases
Disease Progression
Female
Follow-Up Studies
Humans
Hungary
Logistic Models
Lupus Erythematosus, Systemic
Male
Middle Aged
Polymyositis
Probability
Prognosis
Retrospective Studies
Scleroderma, Systemic
egyetemen (Magyarországon) készült közlemény
Severity of Illness Index
Sjogren's Syndrome
Time Factors
Vasculitis
Megjelenés:Clinical and Experimental Rheumatology. - 21 : 3 (2003), p. 313-320. -
További szerzők:Csiki Zoltán (1962-) (belgyógyász, allergológus, klinikai immunológus, reumatológus) Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Ben, Thomas Kiss Emese (1960-) (belgyógyász, immunológus) Zeher Margit (1957-2018) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Szűcs Gabriella (1963-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Dankó Katalin (1952-2021) (belgyógyász, allergológus és klinikai immunológus) Szegedi Gyula (1936-2013) (belgyógyász, immunológus)
Internet cím:elektronikus változat
Borító:

4.

001-es BibID:BIBFORM007049
Első szerző:Bodolay Edit (belgyógyász, allergológus és klinikai immunológus)
Cím:Osteoporosis in mixed connective tissue disease / Bodolay, E., Bettembuk, P., Balogh, A., Szekanecz, Z.
Dátum:2003
ISSN:0770-3198 (Print)
Megjegyzések:The existence of osteoporosis in 58 postmenopausal women with mixed connective tissue disease (MCTD) was investigated. The mean bone mineral density assessed by dual energy X-ray absorptiometry in the lumbar spine was decreased in 25.8% of the patients, reflecting osteoporosis (T score < -2.5). In the femoral neck there was no significant difference between the BMD of MCTD patients and that of age-matched, healthy postmenopausal women. Low bone mineral density was found among patients on, as well as off, corticosteroids. The extent of bone loss was associated with disease duration, as well as corticosteroid therapy. Serum osteocalcin levels were lower in MCTD patients than in controls. Lower serum oestradiol, testosterone and dehydroepiandrosterone sulphate levels were detected in MCTD patients than in controls. Thus, MCTD may be associated with increased bone loss. Pathogenic factors may include the disease itself, corticosteroid therapy, impaired osteoblast function, and low serum sex hormone levels.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Absorptiometry, Photon
Age Distribution
Aged
Bone Density
Case-Control Studies
Cohort Studies
Comorbidity
Estrogens
Female
Humans
Incidence
Middle Aged
Mixed Connective Tissue Disease
Osteocalcin
Osteoporosis, Postmenopausal
Probability
Prognosis
Severity of Illness Index
Statistics, Nonparametric
egyetemen (Magyarországon) készült közlemény
Megjelenés:Clinical Rheumatology. - 22 : 3 (2003), p. 213-217. -
További szerzők:Bettembuk Péter Balogh Á. (orvos) Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus)
Internet cím:elektronikus változat
DOI
elektronikus változat
Borító:

5.

001-es BibID:BIBFORM089545
035-os BibID:(WOS)000600601200003 (Scopus)85097310520
Első szerző:Burmester, Gerd R.
Cím:Evolving the comprehensive management of rheumatoid arthritis : identification of unmet needs and development of practical and educational tools / G. R. Burmester, J. M. Álvaro-Gracia, N. Betteridge, J. Calvo Alén, B. Combe, P. Durez, B. Fautrel, R. J. O. Ferreira, C. Gabay, A. Iagnocco, C. Montecucco, M. štergaard, S. Ramiro, A. Rubbert-Roth, T. Stamm, Z. Szekanecz, P. C. Taylor, M. van de Laar
Dátum:2020
ISSN:0392-856X
Megjegyzések:Objectives: Despite availability of efficacious treatments, unmet needs still exist, preventing optimal and comprehensive management of rheumatoid arthritis (RA). Evolving the management of RA (eRA) is a European-wide educational initiative aiming to support improved patient care through practical and educational tools addressing specific unmet needs. Methods: A multidisciplinary Steering Committee (17 members, 12 countries) identified unmet needs within the management of RA and prioritised those with the greatest impact on patient outcomes. Practical educational tools addressing priority needs were then developed for dissemination and implementation by the rheumatology community across Europe. Results: Five areas of priority need were identified: increasing early recognition of RA and treatment initiation; treating RA to target; optimal, holistic approach to selection of treatment strategy, including shared decision-making; improving identification and management of comorbidities; and non-pharmacological patient management. A suite of 14 eRA tools included educational slides, best-practice guidance, self?assessment questionnaires, clinical checklists, a multidisciplinary team training exercise, an interactive patient infographic, and case scenarios. By April 2020, rheumatology professionals in 17 countries had been actively engaged in the eRA programme; in 11 countries, eRA tools were selected by national leaders in rheumatology and translated for local dissemination. A web platform, with country-specific pages, was developed to support access to the translated tools (https://www.evolvingthemanagementofra.com/). Conclusions: The eRA programme supports comprehensive management of RA across Europe through development and dissemination of practical educational tools. The eRA tools address priority needs and are available free of charge to the rheumatology community.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Rheumatoid arthritis
medical education
delivery of health care
rheumatology
patient care team
Megjelenés:Clinical And Experimental Rheumatology. - 38 (2020), p. 1056-1067. -
További szerzők:Álvaro-Gracia, Jose María Betteridge, Neil Calvo Alén, Jaime Combe, Bernard Durez, Patrick Fautrel, Bruno Ferreira, Ricardo J. O. Gabay, Cem Iagnocco, Annamaria Montecucco, Carlo Maurizio štergaard, Mikkel Ramiro, Sofia Rubbert-Roth, Andrea Stamm, Tanja A. Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Taylor, Peter C. van de Laar, Mart
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
Borító:

6.

001-es BibID:BIBFORM051562
Első szerző:Futó Gábor
Cím:Visualization of DAS28, SDAI, and CDAI : the magic carpets of rheumatoid arthritis / Futó Gábor, Somogyi Attila, Szekanecz Zoltán
Dátum:2014
ISSN:0770-3198
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Clinical Rheumatology. - 33 : 5 (2014), p. 623-629. -
További szerzők:Somogyi Attila Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
DOI
Borító:

7.

001-es BibID:BIBFORM081053
035-os BibID:(PMID)31522318
Első szerző:Gulyás Katalin (reumatológus)
Cím:Effects of 1-year anti-TNF-[alfa] therapies on bone mineral density and bone biomarkers in rheumatoid arthritis and ankylosing spondylitis / Katalin Gulyás, Ágnes Horváth, Edit Végh, Anita Pusztai, Ágnes Szentpétery, Zsófia Pethö, Andrea Váncsa, Nóra Bodnár, Péter Csomor, Attila Hamar, Levente Bodoki, Harjit Pal Bhattoa, Balázs Juhász, Zoltán Nagy, Katalin Hodosi, Tamás Karosi, Oliver FitzGerald, Gabriella Szücs, Zoltán Szekanecz, Szilvia Szamosi, Sándor Szántó
Dátum:2020
ISSN:0770-3198
Megjegyzések:OBJECTIVES: Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) have been associated with generalized and localized bone loss. We conducted a comprehensive study using imaging (dual-energy X-ray absorptiometry, DXA) and laboratory biomarkers in order to determine bone health and to study the effects of anti-tumor necrosis factor (TNF) biologics in RA and AS. PATIENTS AND METHODS: Thirty-six RA and 17 AS patients undergoing 1-year etanercept (ETN) or certolizumab-pegol (CZP) therapy were studied. Bone density was assessed by DXA at baseline and after 12 months. Serum C-reactive protein (CRP), calcium, phosphate, parathyroid hormone (PTH), vitamin D3, osteocalcin, procollagen type I N-propeptide (P1NP), C-terminal telopeptide (βCTX), osteoprotegerin, sclerostin (SOST), Dickkopf-1 (DKK-1), soluble receptor activator nuclear kappa B ligand (sRANKL), and cathepsin K (cathK) levels were determined at baseline and after 6 and 12 months. RESULTS: TNF-α inhibition was clinically effective. Anti-TNF-α halted further bone loss over 1 year. In general, anti-TNF therapy significantly increased P1NP, SOST levels, and the P1NP/βCTX ratios, while decreased DKK-1 and CathK production at different time points in most patient subsets. In the full cohort and in RA, baseline and/or 12-month bone mineral density (BMD) at multiple sites exerted inverse relationships with CRP and βCTX, and positive correlation with SOST. In AS, L2-4 BMD after 1-year biologic therapy inversely correlated with baseline βCTX, while femoral neck BMD rather showed inverse correlations with CRP. CONCLUSIONS: Anti-TNF therapy slowed down generalized bone loss, in association with clinical improvements, in both diseases. TNF blockade may enhance bone formation and suppress joint destruction. Anti-TNF therapy may act inversely on DKK-1 and SOST. Independent predictors of BMD were SOST and βCTX in RA, whilst CRP in AS. Key Points ? One-year anti-TNF therapy halted generalized bone loss in association with clinical improvement in arthritides. ? Anti-TNF therapy may inversely act on DKK-1 and SOST. ? Independent predictors of BMD were SOST and βCTX in RA, while CRP in AS.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Biologics
Bone loss
DKK-1
Erosion
JAK inhibitors
Osteoporosis
Osteoprotegerin
RANKL
Rheumatoid arthritis
Sclerostin
Spondyloarthritis
Syndesmophyte
Megjelenés:Clinical Rheumatology. - 39 : 1 (2020), p. 167-175. -
További szerzők:Horváth Ágnes (1985-) (reumatológus) Végh Edit (1978-) (reumatológus, belgyógyász) Karancsiné Pusztai Anita (1989-) (tudományos segédmunkatárs) Szentpétery Ágnes (1978-) (reumatológus) Pethő Zsófia (1981-) (reumatológus, immunológus) Váncsa Andrea (1972-) (orvos) Bodnár Nóra (1980-) (reumatológus) Csomor Péter (1984-) (biotechnológus) Hamar Attila Béla (1990-) (általános orvos) Bodoki Levente (1986-) (PhD hallgató) Bhattoa Harjit Pal (1973-) (laboratóriumi szakorvos) Juhász Balázs (1973-) (orvos, onkológus) Nagy Zoltán (orvos) Hódosi Katalin Karosi Tamás (1979-) (fül-orr-gégész) FitzGerald, Oliver Szűcs Gabriella (1963-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Szamosi Szilvia (1975-) (belgyógyász, reumatológus) Szántó Sándor (1968-) (belgyógyász, reumatológus)
Pályázati támogatás:K 105073
OTKA
TÁMOP-4.2.4.A/2-11/1-2012-0001
TÁMOP
GINOP-2.3.2-15-2016-00015
GINOP
GINOP-2.3.2-15-2016-00050
GINOP
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

8.

001-es BibID:BIBFORM051257
035-os BibID:WOS:000332485400006
Első szerző:Kádár Gabriella (Szeged)
Cím:Disease activity after the discontinuation of biological therapy in inflammatory rheumatic diseases / Gabriella Kádár, Erika Balázs, Boglárka Soós, Anita Laduver, Péter Keszthelyi, Zoltán Szekanecz, László Kovács
Dátum:2014
ISSN:0770-3198
Megjegyzések:The objectives of this study are to explore the causes of permanent discontinuation of biological therapies in inflammatory rheumatic diseases and to analyse the subsequent course of the disease activity. In this multi-centre retrospective cohort study, data on 126 rheumatoid arthritis, 38 ankylosing spondylitis and 11 psoriatic arthritis patients were analysed, in whom biological therapies had been permanently discontinued. The reasons for the cessation of biologics, the DAS28 or BASDAI disease activity indices at the time of discontinuation and thereafter, and the subsequent occurrence of relapses and the duration of remission or low disease activity were investigated. The most common causes of discontinuation were adverse events (45%), inefficacy (16%) or remission (10%). In rheumatoid arthritis, 33.3% remained in low disease activity after a mean follow-up of 22 months. If the biologic was stopped when the disease was inactive, 60.6% remained inactive, and in all the patients in whom the biologic was discontinued because of long-standing remission, the disease remained inactive. Predictors of remission after discontinuation were low disease activity at stopping the biologic and shorter duration of biological therapy. In contrast, 50% of the ankylosing spondylitis patients relapsed after the withdrawal of anti-TNF therapy. Biologic-free low disease activity can be achieved in at least one third of rheumatoid arthritis patients, and low disease activity at the time of discontinuation is a strong predictor of a subsequent favourable disease course. The likelihood of continued remission after the cessation of a biological therapy is much lower in ankylosing spondylitis.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Clinical Rheumatology. - 33 : 3 (2014), p. 329-333. -
További szerzők:Balázs Erika (Szeged) Soós Boglárka (1988-) (általános orvos) Laduver Anita Keszthelyi Péter Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Kovács László (Szeged)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

9.

001-es BibID:BIBFORM072268
Első szerző:Kardos Zsófia
Cím:Increased frequency of temporal acoustic window failure in rheumatoid arthritis : a manifestation of altered bone metabolism? / Kardos Zsófia, Oláh Csaba, Sepsi Mariann, Sas Attila, Kostyál László, Bóta Tünde, Bhattoa Harjit Pal, Hodosi Katalin, Kerekes György, Tamási László, Bereczki Dániel, Szekanecz Zoltán
Dátum:2018
ISSN:0770-3198
Megjegyzések:Assessment of intracranial vessels includes transcranial Doppler (TCD). TCD performance requires intact temporal acousticwindows (TAW). Failure of TAW (TAWF) is present in 8?20% of people. There have been no reports on TAWF in rheumatoidarthritis (RA). Altogether, 62 female RA patients were included. Among them, 20 were MTX-treated and biologic-free, 20received infliximab, and 22 tocilizumab. The controls included 60 non-RA women. TAWF, temporal bone thickness, and texturewere determined by ultrasound and CT. BMD and T-scores of multiple bones were determined by DEXA. Several bonebiomarkers were assessed by ELISA. In RA, 54.8% of the patients had TAWF on at least one side. Neither TAW could beidentified in 34% of RA subjects. In contrast, only 20.0% of control subjects had TAWF on either or both sides (p < 0.001). In RAvs controls, 53.0 vs 2.9% of subjects exerted the trilayer, Bsandwich-like^ structure of TAW (p < 0.001). Finally, in RA vscontrols, the mean temporal bone thickness values of the right TAW were 3.58 ? 1.43 vs 2.92 ? 1.22 mm (p = NS), while thoseof the left TAW were 4.16 ? 1.56 vs 2.90 ? 1.16 mm (p = 0.001). There was close association between TAWF, bone thickness,and texture (p < 0.05). These TAW parameters all correlated with age; however, TAW failure and texture also correlated withserum osteoprotegerin. TAW bone thickness inversely correlated with hip BMD (p < 0.05). TAWF, thicker, and heterogeneoustemporal bones were associated with RA. These features have been associated with bone loss and OPG production. Bone lossseen in RA may result in OPG release and stimulation of bone formation around TAW.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Biological therapy
BMD
Osteoporosis
Osteoprotegerin
Reumatoid arthritis
Temporal acoustic window failure
Megjelenés:Clinical Rheumatology. - 37 : 5 (2018), p. 1183-1188. -
További szerzők:Oláh Csaba (1972-) (idegsebész) Sepsi Marianna Sas Attila Kostyál László (1974-) (radiológus) Bóta Tünde Bhattoa Harjit Pal (1973-) (laboratóriumi szakorvos) Hódosi Katalin Kerekes György (1973-) (belgyógyász, kardiológus, angiológus) Tamási László Bereczki Dániel (1960-) (neurológus) Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

10.

001-es BibID:BIBFORM007070
Első szerző:Kerekes György (belgyógyász, kardiológus, angiológus)
Cím:Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis, and lipid profile in rheumatoid arthritis / Kerekes, G., Soltesz, P., Der, H., Veres, K., Szabo, Z., Vegvari, A., Szegedi, G., Shoenfeld, Y., Szekanecz, Z.
Dátum:2009
ISSN:1434-9949 (Electronic)
Megjegyzések:Increased cardiovascular mortality has been associated with rheumatoid arthritis (RA). There have been reports indicating that tumor necrosis factor blockers may exert favorable but transient effects on lipid profile, flow-mediated vasodilation (FMD) of the brachial artery, and common carotid intima-media thickness (ccIMT) in RA. In this study, we assessed the effects of rituximab on FMD, ccIMT, and lipid profile. Five female RA patients received two infusions of 1000 mg rituximab i.v. High-resolution B-mode ultrasound was used to assess brachial FMD and ccIMT. We also determined plasma total cholesterol (TC), HDL-C, LDL-C, and triglyceride (Tg) levels. Assessments were performed at baseline, as well as at weeks 2, 6, and 16 after the first infusion. Rituximab (RTX) treatment resulted in a rapid and sustained improvement in FMD. The mean improvement was 30%, 22%, and 81% at weeks 2, 6, and 16, respectively. RTX had little effect on atherosclerosis within this short period of time; however, we observed 10%, 9%, and 2% decreases in ccIMT at weeks 2, 6, and 16, respectively. RTX therapy resulted in 3-11% decrease in TC, as well as 14-35% increase in HDL-C levels. Two infusions of RTX exerted early and sustained favorable effects on endothelial dysfunction, as well as plasma TC and HDL-C levels. RTX may also decrease ccIMT; however, longer follow-up is needed to assess the prolonged effects of RTX on vascular function and lipid profile in RA patients.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Clinical Rheumatology. - 28 : 6 (2009), p. 705-710. -
További szerzők:Soltész Pál (1961-) (belgyógyász, kardiológus) Dér Henrietta (1977-) (orvos) Veres Katalin (1971-) (orvos) Szabó Zoltán (1970-) (belgyógyász, reumatológus) Végvári Anikó (belgyógyász, III. sz. Belgyógyászati Klinika) Szegedi Gyula (1936-2013) (belgyógyász, immunológus) Shoenfeld, Yehuda Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus)
Internet cím:elektronikus változat
DOI
elektronikus változat
Borító:

11.

001-es BibID:BIBFORM056677
Első szerző:Kovács Attila (reumatológus)
Cím:Occurrence of pulmonary rheumatoid nodules following biological therapies / Attila Kovács, Beáta Baksay, Anita Cserenyecz, Klára Molnár, Mária Takács, Zoltán Szekanecz
Dátum:2015
ISSN:0770-3198
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Golimumab
Pulmonary rheumatoid nodules
Rheumatoid arthritis
TNF-[alfa] inhibitor
Tocilizumab
Megjelenés:Clinical Rheumatology. - 34 : 9 (2015), p. 1639-1642. -
További szerzők:Baksay Beáta Cserenyecz Anita Molnár Klára Takács Mária Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus)
Pályázati támogatás:TÁMOP-4.2.4.A/2-11/1-2012-0001
TÁMOP
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
Borító:

12.

001-es BibID:BIBFORM006925
Első szerző:Lakos Gabriella (laboratóriumi szakorvos, transzfúziológus, immunológus)
Cím:Anti-cyclic citrullinated peptide antibody isotypes in rheumatoid arthritis : association with disease duration, rheumatoid factor production and the presence of shared epitope / Lakos Gabriella, Soós Lilla, Fekete Andrea, Szabó Zoltán, Zeher Margit, Horváth Ildikó Fanny, Dankó Katalin, Kapitány Anikó, Gyetvai Ágnes, Szegedi Gyula, Szekanecz Zoltán
Dátum:2008
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Clinical and Experimental Rheumatology. - 26 : 2 (2008), p. 253-260. -
További szerzők:Soós Lilla Fekete Andrea (immunológus) Szabó Zoltán (1970-) (belgyógyász, reumatológus) Zeher Margit (1957-2018) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Horváth Ildikó Fanny (1980-) (belgyógyász, allergológus, klinikai immunológus) Dankó Katalin (1952-2021) (belgyógyász, allergológus és klinikai immunológus) Kapitány Anikó (1979-) (molekuláris biológus) Gyetvai Ágnes Szegedi Gyula (1936-2013) (belgyógyász, immunológus) Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus)
Internet cím:elektronikus változat
elektronikus változat
Borító:
Rekordok letöltése1 2